Warum GLP-1 Gewichtsverlust Plateaus - und wie Sie sie brechen

The weight-loss plateau from GLP-1 drugs like semaglutide isn’t a brick wall — it’s a signaling problem. NIH researchers just opened the hood on what happens inside the neurons these drugs target, and they found a knob we might be able to turn.

For years we knew GLP-1 receptor agonists work in the brain, but the intracellular chain of events was a black box. Now a team led by Andrew Lutas (NIDDK), Michael Krashes (NIDDK), and Claire Gao (NIGMS) has published the first detailed look at that signaling in mouse brain tissue. Their paper in Nature Metabolism uses fluorescence imaging to track semaglutide’s effect on cAMP — cyclic adenosine monophosphate — in real time.

What the drug does inside neurons

The key region is the area postrema, a hindbrain hub for appetite circuits. Semaglutide boosts cAMP there, but not uniformly. “We observed that cAMP responses across cells varied on a continuum,” Krashes said. Some neurons held onto elevated cAMP; others only saw a transient spike, likely because they internalized or degraded their GLP-1 receptors.

That variability explains why some patients respond better than others — and why nearly everyone eventually plateaus. The drug isn’t failing; individual neurons are desensitizing over time.

How to break the plateau

The team then asked: can we push more neurons into the sustained-response camp? They targeted PDE4, the enzyme that degrades cAMP. By inhibiting PDE4 with the existing drug roflumilast, they skewed the population toward sustained cAMP elevation.

In a mouse model, this combination enhanced weight loss beyond semaglutide alone. The implication is clear: modulating how long cAMP hangs around could extend the drug’s effect window, potentially reducing injection frequency and overcoming the plateau that frustrates so many patients.

What’s next

These experiments run over hours in brain slices. The team acknowledges that translating this into a chronic treatment strategy requires studying cAMP dynamics over days and weeks — and in living animals, not just tissue. But the mechanism is concrete, the molecular target is druggable, and roflumilast is already approved for COPD.

If the next wave of GLP-1 therapies looks beyond the receptor and into the signaling cascade, we might finally have a way to keep the weight loss going after the initial honeymoon period ends.

Source: NIH researchers identify avenue for enhanced GLP-1-induced weight loss
Domain: nih.gov